• Please log in or register to access this feature.

Letters to the Editor

You have free access to this content

Letter: the impact of smoking on clinical outcomes after endoscopic dilatation in Crohn's disease

  1. M. Shiraki,
  2. T. Yamamoto

Article first published online: 22 JAN 2013

DOI: 10.1111/apt.12191

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 37, Issue 4, page 500, February 2013

Additional Information

How to Cite

Shiraki, M. and Yamamoto, T. (2013), Letter: the impact of smoking on clinical outcomes after endoscopic dilatation in Crohn's disease. Alimentary Pharmacology & Therapeutics, 37: 500. doi: 10.1111/apt.12191

Author Information

  1. Inflammatory Bowel Disease Centre, Yokkaichi Social Insurance Hospital, Yokkaichi, Japan

Publication History

  1. Issue published online: 22 JAN 2013
  2. Article first published online: 22 JAN 2013
  3. Manuscript Received: 4 DEC 2012
  4. Manuscript Accepted: 4 DEC 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (57K)

References

  • 1
    Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C. Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn's disease. Aliment Pharmacol Ther 2013; 37: 430–7.
    Direct Link:
  • 2
    Yamamoto T, Keighley MR. Smoking and disease recurrence after operation for Crohn's disease. Br J Surg 2000; 87: 398–404.
    Direct Link:
  • 3
    Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136: 441–50.
  • 4
    Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflamm Bowel Dis 2009; 15: 1460–6.
    Direct Link:
View Full Article (HTML) Get PDF (57K)